ストックスクリーナーアプリを入手
1.27
9.29%
-0.13
アフターアワーズ：
1.27
前日終値:
$1.40
開ける：
$1.36
24時間の取引高:
58,398
Relative Volume:
0.48
時価総額：
$38.23M
収益：
-
当期純損益:
$-60.70M
株価収益率:
-0.6225
EPS:
-2.04
ネットキャッシュフロー:
$-61.05M
1週間 パフォーマンス:
-8.63%
1か月 パフォーマンス:
+10.43%
6か月 パフォーマンス:
+18.69%
1年 パフォーマンス:
-60.92%
1日の値動き範囲:
$1.27
$1.37
1週間の範囲:
$1.27
$1.42
52週間の値動き範囲:
$0.87
$3.285
An 2 Therapeutics Inc Stock (ANTX) Company Profile
名前
An 2 Therapeutics Inc
セクター
電話
(650) 331-9090
住所
1800 EL CAMINO REAL, SUITE D, MENLO PARK
ANTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.27 | 38.23M | 0 | -60.70M | -61.05M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2024-08-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-12 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
すべてを表示
An 2 Therapeutics Inc (ANTX) 最新ニュース
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights - Yahoo Finance
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Yahoo Finance
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Yahoo Finance
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Quantisnow
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - Yahoo Finance
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - The Manila Times
Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - Yahoo Finance
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia - Yahoo Finance
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - Yahoo Finance
FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire
Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics - Equitypandit
Latest News | Sun Pharma Shares Rise over 2 Pc as Company to Acquire Checkpoint Therapeutics - LatestLY
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - Yahoo Finance
Black Diamond Therapeutics Reports Fourth Quarter and Full - GlobeNewswire
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open - Yahoo Finance
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - BioSpace
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - Insider Monkey
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial resultsICYMI - Proactive Investors USA
Silver Bullet Therapeutics Announces Podcast Scheduled to Air on March 2, 2025 - Yahoo Finance
Cognition Therapeutics Successfully Passes Pre-defined - GlobeNewswire
Medicenna Therapeutics Corp. - Baystreet.ca
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients - Yahoo Finance
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
Cardiol Therapeutics Inc. - Baystreet.ca
2025-02-16 | APLT Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Filing Deadline in Class Action Lawsuit | NDAQ:APLT | Press Release - Stockhouse Publishing
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting - Yahoo Finance
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - GlobeNewswire
Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase II - Yahoo Finance
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025 - Yahoo Finance
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - Yahoo Finance
Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer - Yahoo Finance
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - Business Wire
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring - Seeking Alpha
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PR Newswire
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis - Yahoo Finance
Tectonic Therapeutic Announces Positive Interim Data from - GlobeNewswire
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 財務データ
収益
当期純利益
現金流量
EPS
An 2 Therapeutics Inc (ANTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chanda Sanjay | Chief Development Officer |
Jan 03 '25 |
Sale |
1.34 |
2,957 |
3,965 |
29,824 |
| Prior Stephen David | Chief Strategy Officer |
Jan 03 '25 |
Sale |
1.34 |
2,029 |
2,721 |
33,313 |
| Eizen Joshua M | See Remarks |
Jan 03 '25 |
Sale |
1.34 |
9,663 |
12,958 |
116,672 |
| Readnour Robin Shane | Director |
Dec 09 '24 |
Buy |
1.43 |
30,772 |
43,984 |
647,573 |
| Readnour Robin Shane | Director |
Dec 06 '24 |
Buy |
1.45 |
19,228 |
27,795 |
629,090 |
| Readnour Robin Shane | Director |
Dec 10 '24 |
Buy |
1.49 |
10,000 |
14,930 |
652,573 |
| Readnour Robin Shane | Director |
Nov 27 '24 |
Buy |
1.42 |
50,000 |
70,840 |
622,573 |
| Readnour Robin Shane | Director |
Nov 26 '24 |
Buy |
1.39 |
25,000 |
34,845 |
597,573 |
| Zakrzewski Joseph S | Director |
Nov 27 '24 |
Buy |
1.40 |
2,000 |
2,800 |
125,199 |
| Readnour Robin Shane | Director |
Nov 19 '24 |
Buy |
1.04 |
150,000 |
155,258 |
560,073 |
3.01%
大文字化:
|
ボリューム (24 時間):